CN113615833A - 一种用于改善心血管的线粒体营养素组合物及应用 - Google Patents
一种用于改善心血管的线粒体营养素组合物及应用 Download PDFInfo
- Publication number
- CN113615833A CN113615833A CN202110747906.XA CN202110747906A CN113615833A CN 113615833 A CN113615833 A CN 113615833A CN 202110747906 A CN202110747906 A CN 202110747906A CN 113615833 A CN113615833 A CN 113615833A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- extract
- composition
- mitochondrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 230000002438 mitochondrial effect Effects 0.000 title claims abstract description 47
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 35
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 45
- 239000000284 extract Substances 0.000 claims abstract description 40
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 claims abstract description 34
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical group NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 34
- 241000037826 Polygonatum kingianum Species 0.000 claims abstract description 21
- 229930003270 Vitamin B Chemical group 0.000 claims abstract description 20
- 239000011720 vitamin B Chemical group 0.000 claims abstract description 20
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 20
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 19
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 19
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 18
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 18
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 18
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 18
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 18
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 18
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical group [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract description 18
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 18
- 239000001656 lutein Substances 0.000 claims abstract description 18
- 235000012680 lutein Nutrition 0.000 claims abstract description 18
- 229960005375 lutein Drugs 0.000 claims abstract description 18
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 18
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 18
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 18
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 18
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 18
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 18
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 18
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 18
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 17
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 17
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical group CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 17
- 229960001009 acetylcarnitine Drugs 0.000 claims abstract description 17
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 17
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 17
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 17
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical group COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 17
- 239000006046 creatine Chemical group 0.000 claims abstract description 17
- 229960003624 creatine Drugs 0.000 claims abstract description 17
- 230000006378 damage Effects 0.000 claims abstract description 17
- 235000003248 hydroxytyrosol Nutrition 0.000 claims abstract description 17
- 229940095066 hydroxytyrosol Drugs 0.000 claims abstract description 17
- 229940004916 magnesium glycinate Drugs 0.000 claims abstract description 17
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 claims abstract description 17
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims abstract description 17
- 229960001763 zinc sulfate Drugs 0.000 claims abstract description 17
- 229910000368 zinc sulfate Inorganic materials 0.000 claims abstract description 17
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 16
- 241000220317 Rosa Species 0.000 claims abstract description 13
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 10
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 5
- 244000269722 Thea sinensis Species 0.000 claims abstract 4
- 241000208340 Araliaceae Species 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 13
- 235000008434 ginseng Nutrition 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 208000007882 Gastritis Diseases 0.000 claims description 5
- 240000002547 Rosa roxburghii Species 0.000 claims description 4
- 235000000640 Rosa roxburghii Nutrition 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 18
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 7
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241001122767 Theaceae Species 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 210000003470 mitochondria Anatomy 0.000 description 11
- 230000003078 antioxidant effect Effects 0.000 description 10
- 241000700198 Cavia Species 0.000 description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 7
- 208000007107 Stomach Ulcer Diseases 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 201000005917 gastric ulcer Diseases 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000011690 Adiponectin Human genes 0.000 description 3
- 108010076365 Adiponectin Proteins 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 230000002180 anti-stress Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 235000019161 pantothenic acid Nutrition 0.000 description 3
- 239000011713 pantothenic acid Substances 0.000 description 3
- 235000008160 pyridoxine Nutrition 0.000 description 3
- 239000011677 pyridoxine Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- MNIQECRMTVGZBM-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC=N2.CN1CCCC1C1=CC=CN=C1 MNIQECRMTVGZBM-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000021479 Cardiovascular injury Diseases 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 1
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000019010 Methylmalonyl-CoA Mutase Human genes 0.000 description 1
- 108010051862 Methylmalonyl-CoA mutase Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000017946 PGC-1 Human genes 0.000 description 1
- 108700038399 PGC-1 Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- RCTGMCJBQGBLKT-UHFFFAOYSA-N Sudan IV Chemical compound CC1=CC=CC=C1N=NC(C=C1C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 RCTGMCJBQGBLKT-UHFFFAOYSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000022888 negative regulation of membrane potential Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/362—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明涉及营养补充剂技术领域,尤其涉及一种用于改善心血管的线粒体营养素组合物及应用。本发明的线粒体营养素组合物包括第一组合物和第二组合物,其中,所述第一组合物包括辅酶Q10、硫辛酸、乙酰半胱氨酸、乙酰肉碱、肌酸、维生素B群、烟酸铬、甘氨酸镁、硫酸锌以及羟基酪醇中的一种或多种;所述第二组合物包括蓝莓提取物、枸杞提取物、叶黄素粉、茶多酚粉、滇黄精提取物、刺梨、人参以及葡萄籽提取物中的一种或多种。本发明的线粒体营养素组合物同时具有延缓衰老、改善胃粘膜损伤以及改善心血管损伤的效果。
Description
【技术领域】
本发明涉及营养补充剂技术领域,尤其涉及一种用于改善心血管的线粒体营养素组合物及应用。
【背景技术】
线粒体是细胞的“发动机”部分,它不仅是细胞内能量生成的关键细胞器,还在细胞凋亡、内钙平衡、氧化应激、脂肪酸代谢等多项重要的生理和生化过程的调节中起着决定性作用。因此,线粒体衰退或功能损伤将导致多种重要的疾病发生,包括神经退行性病变、衰老、肥胖、肿瘤、心脏损伤及肝脏损伤等。
线粒体营养素能够修复线粒体损伤、抑制线粒体中氧化剂产生、能够修复氧化剂损伤、还能充当辅助因子保护线粒体酶及刺激酶的活性。
现有技术中将线粒体营养素用于帕金森治疗、抗疲劳及降血糖治疗等领域中,缺乏将线粒体营养素用于胃粘膜炎症及心血管损伤的案例。
【发明内容】
本发明的技术方案如下:提供一种用于改善心血管的线粒体营养素组合物,包括第一组合物和第二组合物,其中,所述第一组合物包括辅酶Q10、硫辛酸、乙酰半胱氨酸、乙酰肉碱、肌酸、维生素B群、烟酸铬、甘氨酸镁、硫酸锌以及羟基酪醇中的一种或多种;所述第二组合物包括蓝莓提取物、枸杞提取物、叶黄素粉、茶多酚粉、滇黄精提取物、刺梨、人参以及葡萄籽提取物中的一种或多种。
优选地,所述第一组合物包括1~20重量份的辅酶Q10、1~20重量份的硫辛酸、5~20重量份的乙酰半胱氨酸、5~20重量份的乙酰肉碱、5~20重量份的肌酸、5~20重量份的维生素B群、1~20重量份的烟酸铬、1~20重量份的甘氨酸镁、1~20重量份的硫酸锌以及1~20重量份的羟基酪醇。
优选地,所述第二组合物包括1~20重量份的蓝莓提取物、1~20重量份的枸杞提取物、1~20重量份的叶黄素粉、1~20重量份的茶多酚粉、1~20重量份的滇黄精提取物、1~20重量份的刺梨、1~20重量份的人参以及1~20重量份的葡萄籽提取物。
优选地,所述第一组合物包括15重量份的辅酶Q10、15重量份的硫辛酸、5重量份的乙酰半胱氨酸、5重量份的乙酰肉碱、5重量份的肌酸、20重量份的维生素B群、5重量份的烟酸铬、5重量份的甘氨酸镁、15重量份的硫酸锌以及10重量份的羟基酪醇;所述第二组合物包括15重量份的蓝莓提取物、15重量份的枸杞提取物、5重量份的叶黄素粉、5重量份的茶多酚粉、15重量份的滇黄精提取物、3重量份的刺梨、3重量份的人参以及15重量份的葡萄籽提取物。
本发明的另一技术方案如下:提供一种上所述的线粒体营养素组合物的制剂。
优选地,所述制剂的粒径小于或等于第一粒径,所述第一粒径为10~80目。
本发明的另一技术方案如下:提供一种所述的线粒体营养素组合物或上述的制剂在制备用于改善胃粘膜炎症的药物或营养补充剂中的应用。
优选地,所述药物或营养补充剂被制成口服制剂,包括散剂、片剂、冲剂、丸剂、乳剂、颗粒剂、胶囊剂、固体饮料及凝胶软糖中的任意一种。
本发明的另一技术方案如下:提供一种上述的线粒体营养素组合物或上述的制剂在制备用于改善心血管损伤的药物或营养补充剂中的应用。
优选地,所述药物或营养补充剂被制成口服制剂,包括散剂、片剂、冲剂、丸剂、乳剂、颗粒剂、胶囊剂、固体饮料及凝胶软糖中的任意一种。
本发明的有益效果在于:本发明的用于改善心血管的线粒体营养素组合物及制剂包括第一组合物和第二组合物,其中,所述第一组合物包括辅酶Q10、硫辛酸、乙酰半胱氨酸、乙酰肉碱、肌酸、维生素B群、烟酸铬、甘氨酸镁、硫酸锌以及羟基酪醇中的一种或多种;所述第二组合物包括蓝莓提取物、枸杞提取物、叶黄素粉、茶多酚粉、滇黄精提取物、刺梨、人参以及葡萄籽提取物中的一种或多种。本发明的线粒体营养素组合物同时具有延缓衰老、改善胃粘膜损伤以及改善心血管损伤的效果。
【附图说明】
图1为本发明测试例1中血清脂联素水平结果图;
图2为本发明测试例1中主动脉病变面积率结果图;
图3为本发明测试例2中胃溃疡抑制率结果图。
【具体实施方式】
下面结合附图和实施方式对本发明作进一步说明。
[组合物配方]
胃粘膜炎症与氧化应激、线粒体功能障碍密切相关,ROS攻击线粒体导致线粒体膜通透性改变,导致线粒体释放内部物质及膜电位下降,活性氧的产生受到影响,最终导致细胞凋亡。
为实现改善胃粘膜损伤的效果,本发明提供了一种用于改善心血管的线粒体营养素组合物,包括第一组合物和第二组合物,在第一组合物中配伍各线粒体营养素成分以及各应激改善成分,包括辅酶Q10、硫辛酸、乙酰半胱氨酸、乙酰肉碱、肌酸、维生素B群、烟酸铬、甘氨酸镁、硫酸锌以及羟基酪醇中的一种或多种。其中:
辅酶Q10是位于线粒体内膜中的电子载体,能够作为线粒体抗氧化剂使用,具有心肌抗氧化作用;硫辛酸是参与线粒体代谢机制中的一种辅酶,能够被还原为二氢硫辛酸,为硫辛酸乙酰转移酶的辅酶,容易进行氧化还原反应,能够诱导血管平滑肌细胞生产PGC-1α(过氧化物酶增殖活化受体γ-辅助因子1α),刺激线粒体再生,调节ATP产量,并调控核DNA端粒酶;乙酰半胱氨酸为一种线粒体抗氧化剂,具有抗氧化作用;乙酰肉碱为一种次级抗氧化剂,能够将长链脂肪酸转移通过线粒体膜,增加心磷脂水平;肌酸能够增强磷酸肌氨酸的存储,减少ATP的损耗;维生素B群是维护线粒体活性必不可少的成分,其中,B1(硫胺素),是线粒体中α-酮酸脱氢酶、丙酮酸脱氢酶、α-酮戊二酸脱氢酶所催化的关键反应所需要的物质;2(核黄素)是黄素腺嘌呤单核苷酸和黄素腺嘌呤二核苷酸的前体,这二种物质都参与各种氧化还原反应,是线粒体能量生产必须的;B3(烟酸)是烟碱腺嘌呤二核苷酸和烟碱腺嘌呤二核苷酸盐的前体,是线粒体呼吸链复合物I的底物和辅助因子,参与多个三羧酸循环、DNA合成和脂肪代谢的反应;B5(羟酰基泛酸盐)参与脂肪、蛋白质代谢,是三羧酸循环合成脂肪和胆固醇必须组成;B6(吡哆素)是蛋白质代谢二种必须酶的辅酶,参与合成抗体、胃酸;B7(生物素)是多种线粒体酶的辅助因子;叶酸(B9),是造血维生素,对DNA合成尤其线粒体DNA合成必须(参与嘌呤和胸腺嘧啶合成,对线粒体再生和细胞分裂产生影响);B12(钴安素)是线粒体中甲基丙二酰辅酶A变位酶的辅酶;甘氨酸镁提供的二价镁,是人体细胞内主要的阳离子,集聚于线粒体中。以上各成分为线粒体维持功能所必须的成分,为线粒体营养素成分,有助于改善线粒体功能障碍。
烟酸铬提供的铬是一种人体必需的微量元素,是某些酶的激活剂,能够提高抗应激能力;硫酸锌提供锌元素,锌相关酶抑制ATP衰竭导致的细胞凋亡,缺锌会诱导线粒体过氧化物累积;羟基酪醇是一种天然抗氧化剂,具有抗应激反应的作用,能够促进线粒体再生。上述三种成分均具有抗应激反应的作用,为应激改善成分。
本发明第一组分配伍各线粒体营养素成分,以通过修复过氧化损伤来保护线粒体实现改善胃粘膜损伤的效果;同时,在第一组分中配伍各应激改善成分,以通过改善氧化应激反应实现改善胃粘膜损伤的效果。
本发明提供的线粒体营养素组合物,还包括第二组合物。所述第二组合物包括蓝莓提取物、枸杞提取物、叶黄素粉、茶多酚粉、滇黄精提取物、刺梨、人参以及葡萄籽提取物中的一种或多种。其中:
蓝莓提取物中含有大量原花青素,具有抗氧化和保护心血管的作用;枸杞提取物中含有枸杞多糖,具有抗氧化和降血脂的作用;叶黄素粉是一种性能优异的抗氧化剂,可抵御氧自由基在人体内造成细胞与器官损伤,预防机体衰老引发的心血管硬化、冠心病等症状;茶多酚粉具有防治心血管疾病、调节血脂等作用;滇黄精提取物能够降低氧自由基水平,能够增强线粒体抗氧化作用;刺梨中梨超氧化物歧化酶(SOD)及维生素C(VC)含量高,具有抗氧化作用,对于预防和改善心血管方面的疾病有较好效果;人参对心血管具有保护作用;葡萄籽提取物中含有大量原花青素,具有抗氧化和保护心血管的作用。本发明在第二组分中配伍了具有抗氧化作用的蓝莓提取物、枸杞提取物、叶黄素粉、滇黄精提取物、刺梨,以期通过上述各种抗氧化成分与第一组分各成分进行协同作用能够进一步降低氧化应激反应,以通过强化改善氧化应激反应增强改善胃粘膜损伤的效果;同时,发明人发现上述各成分除滇黄精提取物外,还同时具有改善心血管疾病的作用,发明人在上述各成分的基础上另外添加了具有心血管保护作用的茶多酚粉和人参,以期在具有胃粘膜损伤改善作用的同时提高了心血管损伤改善作用。
上述的蓝莓提取物、枸杞提取物、滇黄精提取物以及葡萄籽提取物分别为蓝莓、枸杞、滇黄精以及葡萄籽的水提取物,提取后制成粉状。
在上述的维生素B群中:B1硫胺素5~10份;B2核黄素3~8份;B3烟酸20~40份;B5泛酸10~20份;B6吡哆醇5~10份;B7生物素10~20份;B9叶酸0.5~2份;B12钴胺素0.5~2份。
在一个可选的实施方式中,所述第一组合物包括1~20重量份的辅酶Q10、1~20重量份的硫辛酸、5~20重量份的乙酰半胱氨酸、5~20重量份的乙酰肉碱、5~20重量份的肌酸、5~20重量份的维生素B群、1~20重量份的烟酸铬、1~20重量份的甘氨酸镁、1~20重量份的硫酸锌以及1~20重量份的羟基酪醇;所述第二组合物包括1~20重量份的蓝莓提取物、1~20重量份的枸杞提取物、1~20重量份的叶黄素粉、1~20重量份的茶多酚粉、1~20重量份的滇黄精提取物、1~20重量份的刺梨、1~20重量份的人参以及1~20重量份的葡萄籽提取物。
[制剂的制备]
本发明还提供了一种用于改善心血管的线粒体营养素组合物的制剂,按照如下步骤制备:
S201,按比例称取刺梨和人参,进行粉碎处理,得到第一原料粗粉;
S202,将所述第一原料粗粉进行过筛处理,得到粒径小于或等于80目的第一原料细粉;
S203,按比例称取辅酶Q10、硫辛酸、乙酰半胱氨酸、乙酰肉碱、肌酸、维生素B群、烟酸铬、甘氨酸镁、硫酸锌、羟基酪醇、蓝莓提取物、枸杞提取物、叶黄素粉、茶多酚粉、滇黄精提取物以及葡萄籽提取物,添加至第一原料细粉中进行混合,得到所述线粒体营养素组合物的制剂。
上述的各原料的用量与组合物中各成分的重量比一致。
将步骤S203混合后所得混合物放置在60℃的鼓风干燥箱中干燥2h~3h,灭菌,包装,每小袋10克。
按照上述制备方法所得制剂为颗粒状。
实施例1
本实施例提供了一种用于改善心血管的线粒体营养素组合物的制剂,包括第一组分和第二组分,
所述第一组分包括5重量份的辅酶Q10,5重量份的硫辛酸,15重量份的乙酰半胱氨酸,15重量份的乙酰肉碱,15重量份的肌酸,10重量份的维生素B群,10重量份的烟酸铬,10重量份的甘氨酸镁,5重量份的硫酸锌,5重量份的羟基酪醇;
所述第二组分包括5重量份的蓝莓提取物,5重量份的枸杞提取物,5重量份的叶黄素粉,5重量份的茶多酚粉,5重量份的滇黄精提取物,1重量份的刺梨,1重量份的人参,5重量份的葡萄籽提取物。
实施例2
本实施例提供了一种用于改善心血管的线粒体营养素组合物的制剂,包括第一组分和第二组分,
所述第一组分包括10重量份的辅酶Q10,10重量份的硫辛酸,5重量份的乙酰半胱氨酸,5重量份的乙酰肉碱,5重量份的肌酸,15重量份的维生素B群,10重量份的烟酸铬,10重量份的甘氨酸镁,5重量份的硫酸锌,5重量份的羟基酪醇;
所述第二组分包括10重量份的蓝莓提取物,15重量份的枸杞提取物,5重量份的叶黄素粉,5重量份的茶多酚粉,5重量份的滇黄精提取物,5重量份的刺梨,5重量份的人参,10重量份的葡萄籽提取物。
实施例3
本实施例提供了一种用于改善心血管的线粒体营养素组合物的制剂,包括第一组分和第二组分,
所述第一组分包括15重量份的辅酶Q10,15重量份的硫辛酸,5重量份的乙酰半胱氨酸,5重量份的乙酰肉碱,5重量份的肌酸,20重量份的维生素B群,5重量份的烟酸铬,5重量份的甘氨酸镁,15重量份的硫酸锌,10重量份的羟基酪醇;
所述第二组分包括15重量份的蓝莓提取物,15重量份的枸杞提取物,5重量份的叶黄素粉,5重量份的茶多酚粉,15重量份的滇黄精提取物,3重量份的刺梨,3重量份的人参,15重量份的葡萄籽提取物。
实施例4
本实施例提供了一种用于改善心血管的线粒体营养素组合物的制剂,包括第一组分和第二组分,
所述第一组分包括1重量份的辅酶Q10,1重量份的硫辛酸,15重量份的乙酰半胱氨酸,15重量份的乙酰肉碱,15重量份的肌酸,5重量份的维生素B群,10重量份的烟酸铬,10重量份的甘氨酸镁,5重量份的硫酸锌,5重量份的羟基酪醇;
所述第二组分包括5重量份的蓝莓提取物,5重量份的枸杞提取物,5重量份的叶黄素粉,5重量份的茶多酚粉,5重量份的滇黄精提取物,5重量份的刺梨,5重量份的人参,5重量份的葡萄籽提取物。
实施例5
本实施例提供了一种用于改善心血管的线粒体营养素组合物的制剂,包括第一组分和第二组分,
所述第一组分包括5重量份的辅酶Q10,5重量份的硫辛酸,15重量份的乙酰半胱氨酸,15重量份的乙酰肉碱,15重量份的肌酸,10重量份的维生素B群,10重量份的烟酸铬,10重量份的甘氨酸镁,5重量份的硫酸锌,5重量份的羟基酪醇;
所述第二组分包括1重量份的蓝莓提取物,1重量份的枸杞提取物,1重量份的叶黄素粉,1重量份的茶多酚粉,1重量份的滇黄精提取物,3重量份的刺梨,3重量份的人参,1重量份的葡萄籽提取物。
在上述实施例1至实施例5中,维生素B群按照下述配比,维生素B群总重量100为重量份,其中:B1硫胺素10份;B2核黄素8份;B3烟酸40份;B5泛酸20份;B6吡哆醇10份;B7生物素20份;B9叶酸1份;B12钴胺素1份。
[药效实验]
通过以下动物实验证明本发明实施例的组合物及制剂的效果。
测试例1-改善心血管损伤实验
选取重庆医科大学实验动物中心体重250-300克SPF级健康豚鼠70只,雌雄各半,分7组、每组10只。其中:正常对照组喂养基础饲料,期间自由饮水;其他组第一周全部喂养高脂饲料,期间自由饮水。从第二周起,高脂对照组继续喂养高脂饲料,期间自由饮水;其他5组分别喂食添加组合物的饲料,组合物的添加质量比例均为5%,具体的组合物添加情况参考下表1。
表1:不同组豚鼠的饲料添加情况
第二周结束后,将上述所有实验豚鼠禁食(不禁水)12小时后,采集静脉血,获取血清样本,通过酶联免疫吸附测定(ELISA)测量每组豚鼠血清总脂联素水平,结果如图1所示。与高脂对照组相比,实施例组的血清脂联素水平明显升高,并更接近于正常对照组,说明食用含组合物的饲料后,豚鼠的动脉硬化情况得到改善。
将上述采血后的实验豚鼠处死,分离主动脉,沿前壁中线纵行剖开,用SudanIV染色,用肉眼观察主动脉病变情况,定量病理学测量病变面积及内膜总面积,以病变面积占主动脉内膜总面积的百分比表示动脉硬化的程度,结果如图2所示。高脂对照组豚鼠的主动脉的上述病变情况较实施例自豚鼠的病变情况明显严重,说明食用含组合物的饲料后,豚鼠的主动脉病变情况得到改善。
测试例2-改善胃粘膜炎症实验
选取重庆医科大学实验动物中心体重200-250克SD级健康大鼠,常规饲养一周后,建立大鼠胃溃疡模型:所有大鼠禁食12小时,期间可自由饮水,通过灌胃法施用1ml的96%乙醇诱发急性胃溃疡。建模结束后,按照实验分组情况将大鼠随机分为6组、每组6只。其中:空白组喂养正常饲料,其他5组分别喂食添加组合物的饲料,组合物的添加质量比例均为5%,具体的组合物添加情况参考下表2。
表2:不同组大鼠的饲料添加情况
分组情况 | 空白组 | 实施例1组 | 实施例2组 | 实施例3组 | 实施例4组 | 实施例5组 |
饲料添加 | 无添加 | 组合物1 | 组合物2 | 组合物3 | 组合物4 | 组合物5 |
喂养7天后,将大鼠处死剖腹取出大鼠胃组织,将取下的胃组织沿胃大弯侧切开胃壁,生理盐水冲洗净,分离前后壁,观察前壁内侧面。用双盲法按照Guth标准评定胃黏膜损伤指数(即溃疡指数):病变最大径<1mm为1分、1~2mm为2分、2~3mm为3分、3~4mm为4分。每只鼠的溃疡指数为此小鼠全胃出现总病灶之和的评分。胃溃疡抑制率=[(空白组大鼠胃溃疡指数-干预组大鼠胃溃疡指数)/空白组大鼠胃溃疡指数]×100%。结果如图3所示。与空白组相比,食用含组合物的饲料后,大鼠胃溃疡抑制率明显增高,表明其胃黏膜损伤情况得到改善。
以上所述的仅是本发明的实施方式,在此应当指出,对于本领域的普通技术人员来说,在不脱离本发明创造构思的前提下,还可以做出改进,但这些均属于本发明的保护范围。
Claims (10)
1.一种用于改善心血管的线粒体营养素组合物,其特征在于,包括第一组合物和第二组合物,其中,所述第一组合物包括辅酶Q10、硫辛酸、乙酰半胱氨酸、乙酰肉碱、肌酸、维生素B群、烟酸铬、甘氨酸镁、硫酸锌以及羟基酪醇中的一种或多种;所述第二组合物包括蓝莓提取物、枸杞提取物、叶黄素粉、茶多酚粉、滇黄精提取物、刺梨、人参以及葡萄籽提取物中的一种或多种。
2.根据权利要求1所述的线粒体营养素组合物,其特征在于,所述第一组合物包括1~20重量份的辅酶Q10、1~20重量份的硫辛酸、5~20重量份的乙酰半胱氨酸、5~20重量份的乙酰肉碱、5~20重量份的肌酸、5~20重量份的维生素B群、1~20重量份的烟酸铬、1~20重量份的甘氨酸镁、1~20重量份的硫酸锌以及1~20重量份的羟基酪醇。
3.根据权利要求1或2所述的线粒体营养素组合物,其特征在于,所述第二组合物包括1~20重量份的蓝莓提取物、1~20重量份的枸杞提取物、1~20重量份的叶黄素粉、1~20重量份的茶多酚粉、1~20重量份的滇黄精提取物、1~20重量份的刺梨、1~20重量份的人参以及1~20重量份的葡萄籽提取物。
4.根据权利要求3所述的线粒体营养素组合物,其特征在于,所述第一组合物包括15重量份的辅酶Q10、15重量份的硫辛酸、5重量份的乙酰半胱氨酸、5重量份的乙酰肉碱、5重量份的肌酸、20重量份的维生素B群、5重量份的烟酸铬、5重量份的甘氨酸镁、15重量份的硫酸锌以及10重量份的羟基酪醇;所述第二组合物包括15重量份的蓝莓提取物、15重量份的枸杞提取物、5重量份的叶黄素粉、5重量份的茶多酚粉、15重量份的滇黄精提取物、3重量份的刺梨、3重量份的人参以及15重量份的葡萄籽提取物。
5.权利要求1至4任一项所述的线粒体营养素组合物的制剂。
6.根据权利要求5所述的线粒体营养素组合物的制剂,其特征在于,所述制剂的粒径小于或等于第一粒径,所述第一粒径为10~80目。
7.权利要求1至4任一项所述的线粒体营养素组合物或权利要求5至6任一项所述的制剂在制备用于改善胃粘膜炎症的药物或营养补充剂中的应用。
8.根据权利要求7所述的应用,其特征在于,所述药物或营养补充剂被制成口服制剂,包括散剂、片剂、冲剂、丸剂、乳剂、颗粒剂、胶囊剂、固体饮料及凝胶软糖中的任意一种。
9.权利要求1至4任一项所述的线粒体营养素组合物或权利要求5至6任一项所述的制剂在制备用于改善心血管损伤的药物或营养补充剂中的应用。
10.根据权利要求9所述的应用,其特征在于,所述药物或营养补充剂被制成口服制剂,包括散剂、片剂、冲剂、丸剂、乳剂、颗粒剂、胶囊剂、固体饮料及凝胶软糖中的任意一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110747906.XA CN113615833A (zh) | 2021-07-01 | 2021-07-01 | 一种用于改善心血管的线粒体营养素组合物及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110747906.XA CN113615833A (zh) | 2021-07-01 | 2021-07-01 | 一种用于改善心血管的线粒体营养素组合物及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113615833A true CN113615833A (zh) | 2021-11-09 |
Family
ID=78378976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110747906.XA Pending CN113615833A (zh) | 2021-07-01 | 2021-07-01 | 一种用于改善心血管的线粒体营养素组合物及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113615833A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115634178A (zh) * | 2022-10-13 | 2023-01-24 | 广州华茜药业科技有限公司 | 补充机体细胞能量的线粒体组合物及其制备方法 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2284738A1 (en) * | 1997-03-27 | 1998-10-08 | Michael J. Sole | Nutritional composition for improvements in cell energetics |
WO2004032873A2 (en) * | 2002-10-11 | 2004-04-22 | Creagri, Inc. | Therapeutic combination of carnitine and antioxidant polyphenols |
US20050107338A1 (en) * | 2003-11-17 | 2005-05-19 | Seidman Michael D. | Nutritional supplement enhancing mitochondrial function |
CN101579355A (zh) * | 2009-05-27 | 2009-11-18 | 徐建兴 | 一种维护线粒体功能的营养组合物及其应用 |
CN102150861A (zh) * | 2011-02-15 | 2011-08-17 | 辽宁盛生医药集团有限公司 | 一种具有抗氧化、抗疲劳功能的营养补充剂 |
CN102198195A (zh) * | 2011-05-25 | 2011-09-28 | 遵义陆圣康源科技开发有限责任公司 | 一种具有抗氧化功能的药物组合物 |
CN102726732A (zh) * | 2012-06-04 | 2012-10-17 | 于长富 | 一种防治心血管疾病食品的营养补充剂及其应用 |
CN103251743A (zh) * | 2013-05-30 | 2013-08-21 | 威海康博尔生物药业有限公司 | 一种提高免疫力、改善心脑血管功能、延缓衰老的制剂 |
CN105079009A (zh) * | 2015-08-25 | 2015-11-25 | 厦门金达威集团股份有限公司 | 预防和/或治疗心脑血管疾病的组合物 |
CN106072659A (zh) * | 2016-06-29 | 2016-11-09 | 中国人民解放军第三军医大学第附属医院 | 多元机体抗氧化营养素组合物及其应用 |
CN108392571A (zh) * | 2018-05-28 | 2018-08-14 | 云南中医学院 | 滇黄精在制备线粒体营养素中的应用 |
CN109663021A (zh) * | 2019-03-05 | 2019-04-23 | 通化禾韵现代农业股份有限公司 | 具有抗氧化功能的组合物、制备方法及应用 |
CN112156143A (zh) * | 2020-11-11 | 2021-01-01 | 晨光生物科技集团邯郸有限公司 | 一种具有抗氧化功能的复合营养素组合物 |
-
2021
- 2021-07-01 CN CN202110747906.XA patent/CN113615833A/zh active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2284738A1 (en) * | 1997-03-27 | 1998-10-08 | Michael J. Sole | Nutritional composition for improvements in cell energetics |
WO2004032873A2 (en) * | 2002-10-11 | 2004-04-22 | Creagri, Inc. | Therapeutic combination of carnitine and antioxidant polyphenols |
US20050107338A1 (en) * | 2003-11-17 | 2005-05-19 | Seidman Michael D. | Nutritional supplement enhancing mitochondrial function |
CN101579355A (zh) * | 2009-05-27 | 2009-11-18 | 徐建兴 | 一种维护线粒体功能的营养组合物及其应用 |
CN102150861A (zh) * | 2011-02-15 | 2011-08-17 | 辽宁盛生医药集团有限公司 | 一种具有抗氧化、抗疲劳功能的营养补充剂 |
CN102198195A (zh) * | 2011-05-25 | 2011-09-28 | 遵义陆圣康源科技开发有限责任公司 | 一种具有抗氧化功能的药物组合物 |
CN102726732A (zh) * | 2012-06-04 | 2012-10-17 | 于长富 | 一种防治心血管疾病食品的营养补充剂及其应用 |
CN103251743A (zh) * | 2013-05-30 | 2013-08-21 | 威海康博尔生物药业有限公司 | 一种提高免疫力、改善心脑血管功能、延缓衰老的制剂 |
CN105079009A (zh) * | 2015-08-25 | 2015-11-25 | 厦门金达威集团股份有限公司 | 预防和/或治疗心脑血管疾病的组合物 |
CN106072659A (zh) * | 2016-06-29 | 2016-11-09 | 中国人民解放军第三军医大学第附属医院 | 多元机体抗氧化营养素组合物及其应用 |
CN108392571A (zh) * | 2018-05-28 | 2018-08-14 | 云南中医学院 | 滇黄精在制备线粒体营养素中的应用 |
CN109663021A (zh) * | 2019-03-05 | 2019-04-23 | 通化禾韵现代农业股份有限公司 | 具有抗氧化功能的组合物、制备方法及应用 |
CN112156143A (zh) * | 2020-11-11 | 2021-01-01 | 晨光生物科技集团邯郸有限公司 | 一种具有抗氧化功能的复合营养素组合物 |
Non-Patent Citations (1)
Title |
---|
崔勇: "《新编内科综合治疗学》", 吉林科学技术出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115634178A (zh) * | 2022-10-13 | 2023-01-24 | 广州华茜药业科技有限公司 | 补充机体细胞能量的线粒体组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070026109A1 (en) | Nutritional supplements containing xanthone extracts | |
US20070026108A1 (en) | Nutritional supplement drink containing xanthone extracts | |
CN111035012A (zh) | 一种抗氧化营养组合胶囊及其制备方法 | |
CZ18013U1 (cs) | Kombinovaný preparát pro zlepšení kvality spermatu | |
US20200129463A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
CN112206237A (zh) | 一种含有牛磺酸锌的抗衰老组合物、制备方法及其应用 | |
US20180125915A1 (en) | Natural formulation for treating hangover | |
US9717734B2 (en) | Chewable lipid supplements containing caffeine for increasing alertness, focus and energy | |
CN111436601A (zh) | 一种胰腺癌专用型临床营养配方及其制备 | |
WO2017032270A1 (zh) | 预防和/或治疗心脑血管疾病的组合物 | |
ES2308550T3 (es) | Formulacion para administracion oral que ejerce un efecto reconstituyente sobre el sistema cardiovascular. | |
CN113615833A (zh) | 一种用于改善心血管的线粒体营养素组合物及应用 | |
CN102846673A (zh) | 改善人类精子活动力与质量的组合物 | |
US20140011244A1 (en) | Method for Producing Probiotically Derived Compounds | |
AU2014202925B2 (en) | Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders | |
US10874681B2 (en) | Oral lipid supplements for treating pain and fibromyalgia | |
RU2436415C2 (ru) | Композиция биологически активных веществ на основе бетулина с регулируемой скоростью высвобождения компонентов для снижения степени алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома | |
CN115868628B (zh) | 减肥组合物 | |
BG2697U1 (bg) | Хранителна добавка за поддържане и възстановяване на нормалната функция и архитектоника на черния дроб | |
AU2021103903A4 (en) | Nmn composition for improving cardiovascular and cerebrovascular health and assisting in repairing vascular endothelium and use thereof | |
US11253531B2 (en) | Lipid supplements for reducing nerve action potentials | |
US20220362188A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
CN117958439A (zh) | 抗高原反应胶囊剂及其制备方法 | |
CN112450436A (zh) | 一种具有改善心血管功能的组合物及应用 | |
US20080279968A1 (en) | Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211109 |
|
RJ01 | Rejection of invention patent application after publication |